I Maggio1, V Mollica1, N Brighi1,2, G Lamberti1, L Manuzzi1, A D Ricci1, D Campana3,4. 1. Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. 2. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. 3. NET Team Bologna ENETS Center of Excellence, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. davide.campana@gmail.com. 4. Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. davide.campana@gmail.com.
Abstract
PURPOSE: Insulinomas are a rare type of neuroendocrine tumors, originating in the pancreas, difficult to diagnose and to treat. Due to its rarity, insulinomas are a not well-known pathological entity; thus, the diagnostic process is frequently a medical challenge with many possible differential diagnoses. The diagnostic process varies between non-invasive procedures, such as the fasting test or imaging techniques, and invasive ones. Insulinomas are rarely malignant, but the glycemic imbalance correlated with this tumor can frequently alter the quality of life of the patients and the consequent hypoglycemia can be extremely dangerous. Moreover, insulinomas can be associated with different genetic syndromes, such as Multiple Endocrine Neoplasia 1, accompanied by other specific symptoms. There are many different treatment strategies, depending on the need to control symptoms or control diseases progression, the only curative one being surgery. METHODS AND RESULTS: We reviewed the evidences present in the literature on insulinomas and reported its main clinical characteristics and management strategies. CONCLUSION: The aim of this review of the literature is to present the current knowledge on insulinomas, exploring the main clinical characteristics, the diagnostic tools, and the therapeutic strategies.
PURPOSE:Insulinomas are a rare type of neuroendocrine tumors, originating in the pancreas, difficult to diagnose and to treat. Due to its rarity, insulinomas are a not well-known pathological entity; thus, the diagnostic process is frequently a medical challenge with many possible differential diagnoses. The diagnostic process varies between non-invasive procedures, such as the fasting test or imaging techniques, and invasive ones. Insulinomas are rarely malignant, but the glycemic imbalance correlated with this tumor can frequently alter the quality of life of the patients and the consequent hypoglycemia can be extremely dangerous. Moreover, insulinomas can be associated with different genetic syndromes, such as Multiple Endocrine Neoplasia 1, accompanied by other specific symptoms. There are many different treatment strategies, depending on the need to control symptoms or control diseases progression, the only curative one being surgery. METHODS AND RESULTS: We reviewed the evidences present in the literature on insulinomas and reported its main clinical characteristics and management strategies. CONCLUSION: The aim of this review of the literature is to present the current knowledge on insulinomas, exploring the main clinical characteristics, the diagnostic tools, and the therapeutic strategies.
Authors: Wouter T Zandee; Tessa Brabander; Anela Blažević; Boen L R Kam; Jaap J M Teunissen; Richard A Feelders; Johannes Hofland; Wouter W de Herder Journal: J Clin Endocrinol Metab Date: 2019-04-01 Impact factor: 5.958
Authors: A M Larson; S S Hedgire; V Deshpande; A O Stemmer-Rachamimov; M G Harisinghani; C R Ferrone; U Shah; E A Thiele Journal: Clin Genet Date: 2011-11-29 Impact factor: 4.438
Authors: Damian Wild; Emanuel Christ; Martyn E Caplin; Tom R Kurzawinski; Flavio Forrer; Michael Brändle; Jochen Seufert; Wolfgang A Weber; Jamshed Bomanji; Aurel Perren; Peter J Ell; Jean Claude Reubi Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: Maria A Kouvaraki; Jaffer A Ajani; Paulo Hoff; Robert Wolff; Douglas B Evans; Richard Lozano; James C Yao Journal: J Clin Oncol Date: 2004-12-01 Impact factor: 44.544
Authors: Elina Peltola; Päivi Hannula; Heini Huhtala; Saara Metso; Juhani Sand; Johanna Laukkarinen; Mirja Tiikkainen; Jukka Sirén; Minna Soinio; Pirjo Nuutila; Leena Moilanen; David E Laaksonen; Tapani Ebeling; Johanna Arola; Camilla Schalin-Jäntti; Pia Jaatinen Journal: Eur J Endocrinol Date: 2021-09-01 Impact factor: 6.664